Terms ending in 2028
Every in-force patent on Ambrx, Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,809,511 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 8,048,988 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 8,791,231 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 8,859,802 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 8,012,931 | Modified FGF-21 Polypeptides and Their Uses In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 8,383,365 | Methods of Making FGF-21 Mutants Comprising Non-Naturally Encoded Phenylalanine Derivatives In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 9,079,971 | Modified FGF-21 Polypeptides comprising non-naturally occurring amino acids. In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 9,517,273 | Methods of Treatment Using Modified FGF-21 Polypeptides Comprising Non-Naturally Occurring Amino Acids In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 10,377,805 | Modified FGF-21 Polypeptides Comprising Non-Naturally Encoding Amino Acids and Their Uses In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 10,961,291 | Modified FGF-21 Polypeptides and Their Uses In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| 1 more term end in 2028 · Pro | |||||
10 of 11 patents shown. Soonest term end first, then patent number.
Pro members see all 11, all of them expiring within the 18 months from Nov 19, 2026.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.